Galectin Therapeutics Inc.
Galectin Therapeutics Inc.（GALT）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · GALT · 截至 2026年6月8日
活动摘要
买入笔数
5
P-Purchase only
卖出笔数
51
近12个月
买卖比
0.10
Buy/Sell (by trades)
整体情绪
Galectin Therapeutics Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
GALT 季度内部人买卖趋势
GALT 内幕交易卖出 · GALT 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · GALT CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
GALT 高管卖出股份 · GALT 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 26, 2026 | Jamil Khurram Chief Medical Officer | Option | 568 | $699 | Form 4 |
| May 26, 2026 | Jamil Khurram Chief Medical Officer | Sale | 568 | $2K | Form 4 |
| Feb 6, 2026 | ELDRED KARY Director | Purchase | 300 | $810 | Form 4 |
| Jan 16, 2026 | Uihlein Richard E Director | Award | 13,158 | $40K | Form 4 |
| Jan 5, 2026 | LEWIS JOEL President and CEO · Director | Other | 56,332 | $219K | Form 4 |
| Jan 2, 2026 | LEWIS JOEL President and CEO · Director | Option | 84,000 | — | Form 4 |
| Jan 2, 2026 | LEWIS JOEL President and CEO · Director | Sale | 18,571 | $78K | Form 4 |
| Jan 5, 2026 | LEWIS JOEL President and CEO · Director | Sale | 27,731 | $108K | Form 4 |
| Jan 6, 2026 | LEWIS JOEL President and CEO · Director | Sale | 37,698 | $135K | Form 4 |
| Jan 2, 2026 | CALLICUTT JACK W CFO | Option | 60,000 | — | Form 4 |
| Jan 2, 2026 | CALLICUTT JACK W CFO | Sale | 13,914 | $58K | Form 4 |
| Jan 5, 2026 | CALLICUTT JACK W CFO | Sale | 25,732 | $100K | Form 4 |
| Jan 6, 2026 | CALLICUTT JACK W CFO | Sale | 20,354 | $75K | Form 4 |
| Jan 2, 2026 | Jamil Khurram Chief Medical Officer | Option | 60,000 | — | Form 4 |
| Jan 2, 2026 | Jamil Khurram Chief Medical Officer | Sale | 13,055 | $55K | Form 4 |
| Jan 6, 2026 | Jamil Khurram Chief Medical Officer | Sale | 21,446 | $78K | Form 4 |
| Dec 31, 2025 | Jamil Khurram Chief Medical Officer | Option | 8,125 | $10K | Form 4 |
| Dec 31, 2025 | Jamil Khurram Chief Medical Officer | Sale | 8,125 | $33K | Form 4 |
| Dec 23, 2025 | FREEMAN KEVIN D Director | Purchase | 5,500 | $20K | Form 4 |
| Dec 23, 2025 | ELDRED KARY Director | Purchase | 700 | $3K | Form 4 |
| Dec 17, 2025 | LEWIS JOEL President and CEO · Director | Option | 7,829 | $22K | Form 4 |
| Dec 17, 2025 | LEWIS JOEL President and CEO · Director | Sale | 7,829 | $55K | Form 4 |
| Dec 17, 2025 | Jamil Khurram Chief Medical Officer | Option | 8,500 | $21K | Form 4 |
| Dec 17, 2025 | Jamil Khurram Chief Medical Officer | Option | 6,463 | $14K | Form 4 |
| Dec 17, 2025 | Jamil Khurram Chief Medical Officer | Sale | 8,500 | $60K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 GALT 内幕交易
GALT 内幕交易
Galectin Therapeutics Inc.（GALT）内幕交易数据来源于公司内部人（包括Shlevin Harold H. (Director), LEWIS JOEL (President and CEO · Director), Jamil Khurram (Chief Medical Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。GALT内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Galectin Therapeutics Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
GALT 内幕交易 · 5个问题Galectin Therapeutics Inc.（GALT）的内部人包括高管和董事，如Shlevin Harold H. (Director), LEWIS JOEL (President and CEO · Director), Jamil Khurram (Chief Medical Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026